S. 1040 119th Congress
Drug Competition Enhancement Act
- Health
- Sponsor: Sen. Cornyn, John [R-TX]
- Congress.gov ↗
Latest action, Apr 10, 2025: Placed on Senate Legislative Calendar under General Orders. Calendar No. 43.
How the House voted
The House hasn't taken a roll call on this bill in the Congresses covered.
3 cosponsors
Sponsored by Sen. Cornyn, John [R-TX] (Republican). Cosponsors by party, House members included:
- Democrats
- Republicans
- Independents
Cosponsors
2 D · 1 R
Referred to: Senate: Judiciary Committee
Who lobbied on it
Clients whose quarterly lobbying reports named it, each quarter.
The clients with the most reports naming it. A report's amount covers all of that client's lobbying in the quarter, not just this bill.
7 reports
AMGEN USA INC.
MARSHALL & POPP, LLC
7 reports
ASSOCIATION FOR ACCESSIBLE MEDICINES
THE GIBSON GROUP, LLC
7 reports
BCBSM INC
7 reports
7 reports
COUNCIL FOR INNOVATION PROMOTION (C4IP)
7 reports
7 reports
7 reports
7 reports
PFIZER, INC.
MARSHALL & POPP, LLC
7 reports
PHARMACEUTICAL INDUSTRY LABOR MANAGEMENT ASSOCIATION
E3 STRATEGIC CONSULTING GROUP
7 reports
The top 25 of 46 clients, by reports
| Client | Lobbying firm | Reports | Reports totaling | From | To | House |
|---|---|---|---|---|---|---|
| AMERICA'S HEALTH INSURANCE PLANS INC (AHIP) | 7 | $28.6M | Q1 2025 | Q3 2026 | yes | |
| AMGEN INC | 7 | $21.5M | Q1 2025 | Q3 2026 | yes | |
| AMGEN USA INC. | MARSHALL & POPP, LLC | 7 | $0 | Q1 2025 | Q3 2026 | yes |
| ASSOCIATION FOR ACCESSIBLE MEDICINES | THE GIBSON GROUP, LLC | 7 | $0 | Q1 2025 | Q3 2026 | yes |
| BCBSM INC | 7 | $206K | Q1 2025 | Q3 2026 | yes | |
| BLUE CROSS AND BLUE SHIELD ASSOCIATION | 7 | $8.8M | Q1 2025 | Q3 2026 | yes | |
| BLUE CROSS AND BLUE SHIELD OF FLORIDA INC | 7 | $810K | Q1 2025 | Q3 2026 | yes | |
| CAMBIA HEALTH SOLUTIONS | 7 | $4.6M | Q1 2025 | Q3 2026 | yes | |
| COUNCIL FOR INNOVATION PROMOTION (C4IP) | 7 | $590K | Q1 2025 | Q3 2026 | yes | |
| GSK (FKA GLAXOSMITHKLINE INC.) | 7 | $8.9M | Q1 2025 | Q3 2026 | yes | |
| GUIDEWELL MUTUAL HOLDING CORPORATION | 7 | $40K | Q1 2025 | Q3 2026 | yes | |
| JOHNSON & JOHNSON SERVICES INC | 7 | $15.5M | Q1 2025 | Q3 2026 | yes | |
| PFIZER, INC. | MARSHALL & POPP, LLC | 7 | $0 | Q1 2025 | Q3 2026 | yes |
| PHARMACEUTICAL INDUSTRY LABOR MANAGEMENT ASSOCIATION | E3 STRATEGIC CONSULTING GROUP | 7 | $380K | Q1 2025 | Q3 2026 | yes |
| PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA | 7 | $64.5M | Q1 2025 | Q3 2026 | yes | |
| PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA | CROSSROADS STRATEGIES, LLC | 7 | $0 | Q1 2025 | Q3 2026 | yes |
| PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA | RADIUS ADVOCACY, LLC | 7 | $0 | Q1 2025 | Q3 2026 | yes |
| PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA | MARSHALL & POPP, LLC | 7 | $0 | Q1 2025 | Q3 2026 | yes |
| SANOFI U.S. SERVICES, INC. | MARSHALL & POPP, LLC | 7 | $420K | Q1 2025 | Q3 2026 | yes |
| THE CAMPAIGN FOR SUSTAINABLE RX PRICING | MEHLMAN CONSULTING, INC. | 7 | $630K | Q1 2025 | Q3 2026 | yes |
| TRAVERE THERAPEUTICS | 7 | $1.2M | Q1 2025 | Q3 2026 | yes | |
| ABBVIE INC. | 6 | $7.8M | Q4 2025 | Q3 2026 | yes | |
| ASSOCIATION OF ACCESSIBLE MEDICINES | MEHLMAN CONSULTING, INC. | 6 | $360K | Q4 2025 | Q3 2026 | yes |
| BLUE CROSS AND BLUE SHIELD OF KANSAS INC | 6 | $60K | Q1 2025 | Q3 2026 | yes | |
| CAMPAIGN FOR SUSTAINABLE DRUG PRICING (CSRXP) | WHITMER & WORRALL, LLC | 6 | $300K | Q1 2025 | Q2 2026 | yes |